Guideline on the Management of Melanoma

South African Medical Journal

Volumn 94, Issue 8 III, 2004, Pages 699-707

  Whitaker, Dagmar K ^a   Sinclair, Werner ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ARTICLE; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; FAMILY HISTORY; FOLLOW UP; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH PRACTITIONER; HIGH RISK POPULATION; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALIGNANT LENTIGO; MEDICAL DECISION MAKING; MELANOCYTIC NEVUS; MELANOMA; ORAL CONTRACEPTION; OUTCOMES RESEARCH; PALLIATIVE THERAPY; PATIENT MONITORING; PATIENT REFERRAL; PRACTICE GUIDELINE; PREGNANCY; SKIN BIOPSY; SKIN DEFECT; SOUTH AFRICA; SUN EXPOSURE; TRAINING; TREATMENT INDICATION; TUMOR LOCALIZATION; TUMOR VOLUME;

ADULT; CHILD; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HUTCHINSON'S MELANOTIC FRECKLE; LYMPHATIC METASTASIS; MALE; MASS SCREENING; MELANOMA; NEVUS, PIGMENTED; PREGNANCY; SKIN; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 4444252068     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (124)

1. Coates M, McCredie M, Armstrong B. Cancer in New South Wales: Incidence and Mortality 1993. Sydney: New South Wales Cancer Council, 1996.
2. Jelfs PL, Giles G, Shugg D, et al. Cutaneous malignant melanoma in Australia, 1989. Med J Aust 1994; 161: 182-187.
3. Australian Institute of Health and Welfare and Australasian Association of Cancer Registries. Cancer Series Number 10. Canberra: AIHW, 1998.
4. Australian Cancer Network et al. Clinical Practice Guidelines: The Management of Cutaneous Melanoma. Sydney: ACN, 1999.
5. IARC Monograph on the Evaluation of Carcinogenic Risks to Humans. Solar and Ultraviolet Radiation 1992; 55: 95-122.
6. Setlow RB, Woodhead AD. Temporal changes in the incidence of malignant melanoma: explanation from action spectra. Mutat Res 1994; 307: 365-374.
7. Hussain Z, Pathak MA, Flotte T, et al. Role of Ultraviolet radiation in the induction of melanocytic tumors in hairless mice following 7,12 dimethylbenz(a)anthracene application and ultraviolet radiation. Cancer Res 1991; 51: 4964-4970.
8. Weaterdahl J, Olsson H, Masback A, et al. Use of sunbeds or sunlamps and malignant melanoma in southern Sweden. Am J Epidemiol 1994; 140: 691-699.
9. Holman CD, Armstrong BK. Cutaneous malignant melanoma and indicators of total accumulated exposure to the sun: an analysis separating histogenetic types. J Natl Cancer Inst 1984; 73: 75-82.
10. Elwood JM. Melanoma and sun exposure: contrasts between intermittent and chronic exposure. World J Surg 1992; 16: 157-165.
11. Swerdlow AJ, English J, MacKie RM, et al. Benign melanocytic naevi as a risk factor for malignant melanoma. BMJ Clin Res Ed 1986; 292: 1555-1559.
12. Tucker MA, Fraser MC, Goldstein AM. Risk of melanoma and other cancers in melanoma-prone families. J Invest Dermatol 1993; 100: 350S-355S.
13. Masri GD, Clark WH, Guerry D, et al. Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease. J Am Acad Dermatol 1990; 22: 1042-1048.
14. English DR, Armstrong BK (1988). Identifying people at high risk of cutaneous malignant melanoma: results from a case control study in Western Australia. BMJ Clin Res Ed 1988; 296: 1285-1288.
15. Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: role of physician examination and self-examination of the skin. CA Cancer J Clin 1985; 35: 130-151.
16. Fitzpatrick TB, Rhodes AR, Sober AJ, et al. Primary malignant melanoma of the skin: the call for action to identify persons at risk: to discover precursor lesions: to detect early melanomas. Pigment Cell 1988; 9: 110-117.
17. Menzies SW, Crotty KA, Ingvar C, et al. eds. An Atlas of Surface Microscopy of Pigmented Skin Lesions. Sydney: McGraw-Hill, 1996.
18. Binder M, Swcharz M, Winkler A, et al. Epiluminescence microscopy. A useful test for the diagnosis of pigmented skin lesions for formally trained dermatologists. Arch Dermatol 1985; 131: 286-291.
19. Steiner A, Pehamberger H, Wolff K. In vivo epiluminescence microscopy of pigmented skin lesions. II Diagnosis of small pigmented skin lesions and early detection of malignant melanoma. J Am Acad Dermatol 1987; 17: 584-591,
20. Pehamberger H, Binder M, Steiner A, et al. In vivo epiluminescence microscopy: improvement of early diagnosis of melanoma. J Invest Dermatol 1993; 100: 356S-362S.
21. Mayer J. Systematic review of the diagnostic accuracy of dermatoscopy in detecting malignant melanoma. Med J Aust 1997; 167: 206-210.
22. Holly EA, Kelly JW, Shpall SN, et al. Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol 1987; 17: 459-468.
23. Augustsson A, Stierner U, Rosdahl I, et al. Common and dysplastic naevi as risk factors for cutaneous melanoma in a Swedish population. Acta Derm Venereol 1991; 71: 518-524.
24. Halpern AC, Guerry D, Elder et al. Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. A case-control study. Arch Dermatol 1991; 127: 995-999.
25. Roush GC, Nordlund JJ, Forget B, et al. Independence of dysplastic nevi from total nevi in determining risk for nonfamilial melanoma. Prev Med 1988; 273-279.
26. Kelly JW, Crutcher WA, Sagebiel RW. Clinical diagnosis of dysplastic melanocytic nevi. A clinicopathologic correlation. J Am Acad Dermatol 1986; 14: 1044-1052.
27. Mark R, Dorovitch AP, Mason G. Do all melanomas come from 'moles'? A study of the histological association between melanocytic naevi and melanoma. Australas J Dermatol 1990; 31: 77-80.
28. Sagebiel RW. Melanocytic nevi in histologic association with primary cutaneous melanoma of superficial spreading and nodular types: effect of tumor thickness. J Invest Dermatol 1993; 100: 322S-325S.
29. Skender-Kalnenas TM, English DR, Heenan PJ. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma? J Am Acad Dermatol 1995; 33: 1000-1007.
30. Aitken JF, Duffy DL, Green A, et al. Heterogeneity of melanoma risk in families of melanoma patients. Am J Epidemiol 1994; 140: 961-973.
31. Easton DF, Cox GM, Macdonald AM, et al. Genetic susceptibility to naevi - a twin study. Br J Cancer 1991; 64: 1164-1167.
32. Walton RG, Jacobs AH, Cox AJ. Pigmented lesions in newborn infants. Br J Dermatol 1976; 95: 389-396.
33. Kroon S, Clemmensen OJ, Hastrup N. Incidence of congenital melanocytic nevi in newborn babies in Denmark. J Am Acad Dermatol 1987; 17: 422-426.
34. Osburn K, Schosser RH, Everett MA. Congenital pigmented and vascular lesions in newborn infants. J Am Acad Dermatol 1987; 16: 788-792.
35. Illig L, Weidner F, Hundeiker M, et al. Congenital nevi less than or equal to 10 cm as precursors to melanoma. Arch Dermatol 1985; 121: 1274-1281.
36. Rhodes AR, Sober AJ, Day CL, et al. The malignant potential of small congenital nevocellular nevi. J Am Acad Dermatol 1982; 6: 230-241.
37. Marghoob AA, Schoenbach SP, Kopf AW, et al. Large congenital metanocytic nevi and the risk for the development of malignant melanoma. A prospective study. Arch Dermatol 1996; 132: 170-175.
38. Ruiz-Maldonado R, Tamayo L, Laterza AM,et al. Giant pigmented nevi: clinical, histopathologic, and therapeutic considerations. J Pediatr 1992; 120: 906-911.
39. Lorentzen M, Pers M, Bretteville-Jensen G. The incidence of malignant transformation in giant pigmented nevi. Scand J Plast Reconstr Surg 1977; 11: 163-167.
40. Rhodes AR. Congenital nevomelanocytic nevi. Histologic patterns in the first year of life and evolution during childhood. Arch Dermatol 1986; 122: 1257-1262.
41. Rhodes AR, Wood WC, Sober AJ, et al. Nonepidermal origin of malignant melanoma associated with giant congenital nevocellular nevus. Plast Reconstr Surg 1981; 67: 782-790.
42. Kadonaga JN, Frieden IJ, Neurocutaneous melanosis: definition and review of the literature. J Am Acad Dermatol 1991; 24: 747-755.
43. Frieden IJ, Williams ML, Barkovich AJ. Giant congenital melanocytic nevi: brain magnetic resonance findings in neurologically asymptomatic children. J Am Acad Dermatol 1994; 31: 423-429.
44. Vorobiof DA. Malignant melanoma: the new revised staging system. Dermatology Review 2001; Winter: 43.
45. American Joint Committee on Cancer (AJCC). Cancer Staging Manual. 6th ed. Philadelphia: Lippincott-Raven, 2002: 211-213.
46. Anonymous. NIH Consensus Conference. Diagnosis and Treatment of Early Melanoma. JAMA 1992; 268: 1314-1319.
47. Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate thickness melanomas 1 to 4mm. Results of a multi-institutional randomized surgical trial. Ann Surg 1993; 218: 262-269.
48. Veronessi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991; 126: 438-441.
49. Ringborg U, Andersson R, Eldh J, et al. Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm. cancer 1996; 77: 1809-1814.
50. O'Rourke MG, Altmann CR. Melanoma recurrence after excision. Is a wide margin justified? Ann Surg 1993; 217: 2-5.
51. Balch CM, Soong SJ, Shaw HM. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM, Houghton AN, Milton GW, et al., eds. Cutaneous Melanoma. Philadelphia: Lippincott 1992.
52. McCarthy WH, Shaw HM. The influence of prognostic factors on melanoma management. In: Lejeune FJ, Chaudhuri PK, Das Gupta TK, eds. Malignant Melanoma. New York: McGraw Hill, 1994.
53. Kelly JW, Sagebiel RW, Clyman S, et al. Thin level IV malignant melanoma. A subset in which level is the major prognostic indicator. Ann Surg 1985; 202: 98-103.
54. Shaw HM, McCarthy WH, McCarthy SW, et al. Thin malignant melanoma and recurrence potential. Arch Surg 1987; 122: 1147-1150.
55. Veronesi U, Adamus J, Bandiera DC, et al. Stage I melanoma of the limbs. Immediate versus delayed node dissection. Tumori 1980; 66: 373-396.
56. Coit D, Sauven P, Brennan M. Prognosis of thick cutaneous melanoma of the trunk and extremity. Arch Surg 1990; 125: 322-326.
57. McCarthy WH, Shaw HM, Cascinelli N, et al. Elective lymph node dissection: two perspectives. World J Surg. 1992; 16: 203-213.
58. Crowley NJ. Lymph node dissection in malignant melanoma. The case against elective lymphadenectomy. Surg Oncol Clin North Am 1992; 1: 223-246.
59. Lyons JH, Cockerell CJ. Elective lymph node dissection for melanoma. J Am Acad Dermatol 1994; 30: 467-480.
60. Slingluff CL, Stidham KR, Ricci WM, et al. Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients. Ann Surg 1994; 219: 120-130.
61. Harris MN, Shapiro RL, Roses DF. Malignant melanoma. Primary surgical management (excision and node dissection) based on pathology and staging. Cancer 1995; 75: 715-725.
62. Coates AS, Ingvar CI, Petersen-Schaefer K, et al. Elective lymph node dissection in patients with primary melanoma of the trunk and limbs treated at the Sydney Melanoma Unit from 1960 to 1991. J Am Coll Surg 1995; 180: 402-409.
63. Reintgen DS, Cox EB, McCarty KS, et al. Efficacy of elective lymph node dissection in patients with intermediate thickness melanoma. Ann Surg 1983; 198: 379-385.
64. Drepper H, Kohler CO, Bastian B, et al. Benefit of elective lymph node dissection in subgroups of melanoma patients. Results of a multicenter study of 3616 patiens. Cancer 1993 72: 741-749.
65. Rompel R, Garbe C, Buttner P, et al. Elective lymph node dissection in primary malignant melanoma: a matched-pair analysis. Melanoma Res 1995; 5: 189-194.
66. Balch CM Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996; 224: 255-266.
67. Calabro A, Singletary SE, Balch CM. PAtterns of relapse in 1001 cunsecutive patients with melanoma nodal metastases. Arch Surg 1989; 124: 1051-1055.
68. O'Brien CJ, Gianoutsos MP, Morgan MJ. Neck dissection for cutaneous malignant melanoma. World J Surg 1992; 16: 222-226
69. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative mapping for early, stage melanoma. Arch Surg 1992; 127: 392-399.
70. Morton DL, Wen DR, Cochran AJ. Management of early-stage melanoma by intra-operative lymphatic mapping and selective lymphadenectomy. Surg Oncol Clin North Am 1992; 1: 247-259.
71. Morton DL, Wen DR, Foshag LJ, et al. Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanomas of the head and neck. J Clin Oncol 1993; 11: 1751-1756.
72. Thompson JF, McCarthy WH, Bosch CM, et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995; 5: 255-260.
73. Uren RF, Howman-Giles RB, Shaw HM, et al. Lymphoscintigraphy in high-risk melanoma of the trunk: predicting draining node groups, defining lymphatic channels and locating the sentinel node. J Nucl Med 1993; 34: 1435-1440.
74. Uren RF, Howman-Giles R, Thompson JF, et al. Lymphoscintigraphy to identify sentinel nodes in patients with melanoma. Melanoma Res 1994; 4: 395-399.
75. Balch CM, Houghton AN. Diagnosis of metastatic melanoma at distant sites. In: Balch CM, Houghton AN, Milton GW, et al., eds. Cutaneous Melanoma. Philadelphia: Lippincott, 1992;
76. Velez A, Walsh D, Karakousis CP. Treatment of unknown primary melanoma. Cancer 1991; 68: 2579-2581.
77. Milton GW, Shaw HM, McCarthy WH. Occult primary malignant melanoma: factors influencing survival. Br J Surg 1977; 64: 805-808.
78. Norman J, Cruse CW, Wells KE, et al. Metastatic melanoma with an unknown primary. Ann Plast Surg 1992; 28: 81-84.
79. Krementz ET, Ryan RF, Muchmore JH, et al. Hyperthermic regional perfusion for melanoma of the limbs. In: Balch CM, Houghton AN, Milton GW, et al., eds. Cotaneous Melanoma. Philadelphia: Lippincott, 1992:
80. Thompson JF. Management strategies for locally advanced primary and secondary malignancies. Cancer Forum 1993; 17: 224-226.
81. Thompson JF, Waugh RC, Saw RPM, et al. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat 1994; 7: 188-192.
82. Koops HS, Kroon BBR, Lejeune FJ. Management of local recurrence, satellites, and in transit metastases of the limbs with isolation perfusion. In: Lejeune FJ, Chaudhuri PK, Das Gupta TK, eds. Malignant Melanoma. New York: McGraw Hill, 1994:
83. Coates A, Gebski V, Bishop JF, et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 1987; 317: 1490-1495.
84. Coates A, Gebski V, Signorini D et al. Prognostic quality-of-life scores during chemotherapy for advanced breast cancer. Australian & New Zealand Breast Cancer Trials Group. J Clin Oncol 1992; 10: 1833-1838.
85. Coates A, Thomson D, McLeod GR, et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer 1993; 29A: 1731-1734.
86. Houghton AN, Balch CM. Treatment for advanced melanoma. In: Balch CM, Houghton AN, Milton GW, et al., eds. Cutaneous Melanoma. Philadelphia: Lippincott, 1992:
87. Peters LJ, Byers RM, Ang KK. Radiotherapy for melanoma. In: Balch CM, Houghton AN, Milton GW et al., eds. Cutaneous Melanoma. Philadelphia: Lippincott.
88. Rosenthal MA, Bull CA, Coates A, et al. Synchronous cisplatin infusion during radiotheraphy for the treatment of metastatic melanoma. Eur J Cancer 1991; 27: 1564-1566.
89. Stevens G, Firth I, Coates AS. Cerebral metastases from malignant melanoma. Radiother Oncol 1992; 23 185-191.
90. Singletary SE, Balch CM. Recurrent regional metastases and their management. In: Balch CM, Houghton AN, Milton GW, et al., eds. Cutaneous Melanoma. Philadelphia: Lippincott, 1992:
91. Burmeister H, Smithers BM, Poulsen M, et al. Radiation therapy for nodal disease in malignant melanoma. World J Surg 1995; 19: 369-371.
92. McCarthy WH, Shaw HM, Thompson JF, et al. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow up study. Surg Gynecol Obstet 1988; 166: 497-502.
93. Kelly JW, Blois MS, Sagebiel RW. Frequency and duration of patient follow-up after treatment of a primary malignant melanoma. J Am Acad Dermatol 1985; 13: 756-760.
94. Drake LA, Ceilley RI, Cornelison RL, et al. Guidelines for the care of malignant melanoma. J Am Acad Dermatol 1993; 28: 638-641.
95. Browman GP, Levine MN, Mohide EA, et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995; 13: 502-512.
96. Weiss M, Loprinzi CL, Creagan ET, et al. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanoma. JAMA 1995; 274: 1703-1705.
97. Ross MI, Stern SJ, Wanebo HJ. Mucosal melanomas. In: Balch CM, Houghton AN, Milton GW, et al., eds. Cutaneous Melanoma. Philadelphia: Lippincott, 1992:
98. Wong JH, Morton DL. Management of primary mucosal melanoma. In: Lejeune FJ, Chaudhuri PK, Dos Gupta TK, eds. Malignant Melanoma. New York: McGraw Hill, 1994; 337-342.
99. Sutherland CM, Chmiel JS, Henson DE, et al. Patient characteristics and methods of treatment of mucous membrane melanoma in the United States of America. J Am Coll Surg 1994; 179: 561-566.
100. Sutherland CM, Mather FJ, Muchmore JH, et al. Acral lentiginous melanoma. Am J Surg 1993; 116: 64-67.
101. Ridgeway CA, Hieken TJ, Ronan SG, et al. Acral lentiginous melanoma. Arch Surg 1995; 130: 88-92.
102. Cascinelli N, Zurrida S, Galimberti V, et al. Acral lentiginous melanoma. A histological type without prognostic significance. J Dermatol Surg Oncol 1994; 20: 817-822.
103. Fleegler EJ. A surgical approach to melanonychia striata. J Dermatol Surg Oncol 1992; 18: 708-714.
104. Finley RK, Driscoll DL, Blumenson LE, et al. Subungual melanoma: an eighteen-year review. Surgery 1994; 116: 96-100.
105. Hayes IM, Thompson JF, Quinn MJ. Malignant melanoma of the toenail apparatus. J Am Coll Surg 1995; 180: 583-588.
106. O'Toole FA, Stephens R, Young MM, et al. Subungual melanoma: a relation to direct injury? J Am Acad Dermatol 1995; 33: 525-528.
107. Milton GW, Shaw HM, McCarthy WH. Subungual melanoma: a disease entity separate from other forms of cutaneous melanoma. Australas J Dermatol 1985; 26: 61-64.
108. Heaton KM, El-Naggar A, Ensign LG, et al. Surgical management and prognostic factors in patients with subungual melanoma. Ann Surg 1994; 219: 197-204.
109. Smithers BM, McLeod GR, Little JH. Desmoplastic melanoma: patterns of recurrence. World J Surg 1992; 16: 186-190.
110. Baer SJ, Schultz D, Synnestvedt M, et al. Desmoplasia and nourotropism. Cancer 1995; 76: 2242-2247.
111. Kang S, Barnhill RL, Mihm MC, et al. Multiple primary cutaneous melanomas. Cancer 1992; 70: 1911-1916.
112. Slingluff CL, Vollmer RT, Seigler HF. Multiple primary melanoma: incidence and risk factors in 283 patients. Surgery 1993; 113: 330-339.
113. Ariyan S, Poo WJ, Bolognia J, et al. Multiple primary melanomas: data and significance. Plast Reconstr Surg 1995; 96: 1384-1389.
114. Tucker MA, Crutcher WA, Hartge P, et al. Familial and cutaneous features of dysplastic nevi: a case-control study. J Am Acad Dermatol 1993; 28: 558-564.
115. Lucchina LC, Barnhill RL, Duke DM, et al. Familial cutaneous melanoma. Melanoma Res 1995; 5: 413-418.
116. Gupta BK, Piedmonte MR, Karakousis CP. Attributes and survival patterns of multiple primary cutaneous malignant melanoma. Cancer 1991; 67: 1984-1989.
117. Ceballos PI, Ruiz-Maldonado R, Mihm MC. Melanoma in children. N Engl J Med 1995; 332: 656-662.
118. Piepkorn M. On the nature of histologic observations: the case of the Spitz nevus. J Am Acad Dermatol 1995; 32: 248-254.
119. Driscoll MS, Grin-Jorgensen CM, Grant-Kels JM. Does pregnancy influence the prognosis of malignant melanoma? J Am Acad Dermatol 1993; 29: 619-630.
120. Holly EA, Cress RD. Melanoma and pregnancy. In: Gallagher RP, Elwood JM, eds. Epidemiological Aspects of Cutaneous Malignant Melanoma. Boston: Kluwer, 1994:
121. Travers RL, Sober AJ, Berwick M, et al. Increased thickness of pregnancy associated melanoma, Br J Dermatol 1995; 132: 876-883.
122. Mansfield PF, Lee JE, Balch CM. Cutaneous melanoma: current practice and surgical controversies. Curr Probl Surg 1994; 31; 253-374.
123. Holly EA, Cress RD, Ahn DK. Cutaneous melanoma in women: ovulatory life, menopause, and use of exogenous estrogens. Cancer Epidemiol Biomarkers Prev 1994; 3: 661-668.
124. Holly EA, Cress RD, Ahn DK. Cutaneous melanoma in women. III Reproductive factors and oral contraceptive use. Am J Epidemiol 1995; 141: 943-950.